Authors:
Address: Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands. a.h.e.roukens@lumc.nl
Journal:

Publication:
Free Text: Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study.

abstract

BACKGROUND:

yellow fever vaccination (YF-17D) can cause serious adverse events (SAEs). The mechanism of these SAEs is poorly understood. Older age has been identified as a risk factor. We tested the hypothesis that the humoral immune response to yellow fever vaccine develops more slowly in Elderly than in younger subjects.

METHOD:

We vaccinated young volunteers (18-28 yrs, N = 30) and elderly travelers (60-81 yrs, N = 28) with YF-17D and measured their neutralizing antibody titers and plasma YF-17D RNA copy numbers before vaccination and 3, 5, 10, 14 and 28 days after vaccination.

RESULTS:

Ten days after vaccination seroprotection was attained by 77% (23/30) of the young participants and by 50% (14/28) of the elderly participants (p = 0.03). Accordingly, the Geometric Mean Titer of younger participants was higher than the GMT of the elderly participants. At day 10 the difference was +2.9 IU/ml (95% CI 1.8-4.7, p = 0.00004) and at day 14 +1.8 IU/ml (95% CI 1.1-2.9, p = 0.02, using a mixed linear model. viraemia was more common in the elderly (86%, 24/28) than in the younger participants (60%, 14/30) (p = 0.03) with higher YF-17D RNA copy numbers in the elderly participants.

CONCLUSIONS:

We found that elderly subjects had a delayed antibody response and higher viraemia levels after yellow fever primovaccination. We postulate that with older age, a weaker immune response to yellow fever vaccine allows the attenuated virus to cause higher viraemia levels which may increase the risk of developing SAEs. This may be one piece in the puzzle of the pathophysiology of YEL-AVD.

TRIAL REGISTRATION:

Trialregitser.nl NTR1040.

Related Articles
Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Hum Vaccin. 2010
Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.
Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, Kanesa-Thasan N, Feroldi E, Reid M. Hum Vaccin. 2010 Nov; 6(11):906-14. Epub 2010 Nov 1.
Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial.
PLoS One. 2008
Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial.
Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG. PLoS One. 2008 Apr 23; 3(4):e1993. Epub 2008 Apr 23.
Yellow fever 17D vaccine safety and immunogenicity in the elderly.
Hum Vaccin. 2005
Yellow fever 17D vaccine safety and immunogenicity in the elderly.
Monath TP, Cetron MS, McCarthy K, Nichols R, Archambault WT, Weld L, Bedford P. Hum Vaccin. 2005 Sep-Oct; 1(5):207-14. Epub 2005 Sep 2.
Review Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
Vaccine. 2011
Review Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T. Vaccine. 2011 Jun 20; 29(28):4544-55. Epub 2011 May 5.
Review Yellow fever vaccine: past, present and future.
Expert Opin Biol Ther. 2008
Review Yellow fever vaccine: past, present and future.
Roukens AH, Visser LG. Expert Opin Biol Ther. 2008 Nov; 8(11):1787-95.

To top • Home

---

Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer • webmaster